Similarly, only two-thirds of the HER-2/neu overexpressing pancreatic tumours demonstrated AKT activation; this suggests that some minor fraction of tumours have an additional defect in the signalling pathway from HER-2/neu to AKT that prevents AKT activation despite HER-2/neu overexpression. This evidence concerns the gene AKT1 and pancreatic neoplasm.